(2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methanamine | 561297-93-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methanamine
• 英文别名: [2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methanamine
• CAS: 561297-93-6
• 化学式: C₈H₉F₃N₂O
• mdl: MFCD09739720
• 分子量: 206.167
• InChiKey: MASUAGXDVXJRDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  环戊基乙酰氯 、 (2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methanamine 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 以27 %的产率得到2-cyclopentyl-N-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)acetamide
  参考文献：
  名称：

  AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS

  摘要：

  The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2/Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particularly in the treatment of disorders of the central nervous system (CNS), such as, for example, epilepsy and neurodegenerative disorders, and of the peripheral nervous system (PNS), such as, for example, chronic and neuropathic pain.

  公开号：

  WO2024121046A1

文献信息

• [EN] ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLAMIDE EN TANT QU'AGENTS BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2012053186A1

  公开（公告）日：2012-04-26

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及具有对电压门控钠通道（如TTX-S通道）具有阻塞活性的芳基酰胺衍生物，用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的这类疾病中使用这些化合物和组合物。
• [EN] PHENYL- SULFONYL DERIVATIVES AS MEDIATORS OF TRPA1 RECEPTOR ACTIVITY FOR THE TREATMENT OF PAIN<br/>[FR] DÉRIVÉS DE PHÉNYLSULFONYLE EN TANT QUE MÉDIATEURS DE L'ACTIVITÉ DE RÉCEPTEUR TRPA1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ORION CORP

  公开号：WO2012152983A1

  公开（公告）日：2012-11-15

  Compounds of formula I, wherein A and R1-R7, are as defined in the claims, exhibit TRPA1 activity and useful as TRPA1 modulators.

  式I的化合物，其中A和R1-R7如索权中所定义，表现出TRPA1活性，并且作为TRPA1调节剂是有用的。
• KCNQ Potentiators
  申请人：Eli Lilly and Company

  公开号：US20200247752A1

  公开（公告）日：2020-08-06

  Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.

  针对钾通道的小分子增效剂（例如Kv7增效剂，也称为KCNQ增效剂），包括这类化合物的组合物，以及利用这类化合物治疗由运动神经元兴奋性变化引起的肌萎缩侧索硬化症和其他神经系统疾病的方法，包括但不限于原发性侧索硬化症、假性延髓麻痹、进行性延髓麻痹、进行性肌萎缩和癫痫。
• ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20140336377A1

  公开（公告）日：2014-11-13

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及一种芳基酰胺衍生物，其具有阻断电压门控钠通道（如TTX-S通道）的活性，并且在涉及电压门控钠通道的疾病和疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及电压门控钠通道的这种疾病的预防或治疗中的使用。
• KCNQ potentiators
  申请人：Eli Lilly and Company

  公开号：US11208383B2

  公开（公告）日：2021-12-28

  Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.

  小分子钾通道增效剂（如 Kv7 增效剂--也称为 KCNQ 增效剂）、包括此类化合物的组合物以及使用此类化合物治疗肌萎缩侧索硬化症和其他由运动神经元兴奋性变化引起的神经系统疾病的方法，包括但不限于原发性侧索硬化症、假性球麻痹、进行性球麻痹、进行性肌肉萎缩和癫痫。